Anthem Biosciences IPO: GMP, Subscription, and Investment Outlook Explained
India’s pharmaceutical and biotech sectors have seen an upswing in public interest, and Anthem Biosciences’ IPO is the latest to ride that wave. With a strong response from institutional and retail investors, a rising Grey Market Premium (GMP), and positive analyst recommendations, the IPO has become one of the most discussed issues of July 2025. … Read more